Cargando…
The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134726/ https://www.ncbi.nlm.nih.gov/pubmed/37103747 http://dx.doi.org/10.1007/s40120-023-00477-6 |
_version_ | 1785031820295798784 |
---|---|
author | Feng, Yijie Cui, Yiqin Jin, Jianing Huang, Siyi Wei, Jia Yao, Mei Zhou, Dongming Mao, Shanshan |
author_facet | Feng, Yijie Cui, Yiqin Jin, Jianing Huang, Siyi Wei, Jia Yao, Mei Zhou, Dongming Mao, Shanshan |
author_sort | Feng, Yijie |
collection | PubMed |
description | INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore the alterations in the gut microbiota in SMA and the potential relationship between altered microbiota and lipid metabolic disorders. METHODS: Fifteen patients with SMA and 17 gender- and age-matched healthy controls were enrolled in the study. Feces and fasting plasma samples were collected. 16S ribosomal RNA sequencing and nontargeted metabolomics analysis were performed to explore the correlation between microbiota and differential lipid metabolites. RESULTS: No significant difference was found in microbial diversity (α- and β-diversity) between the SMA and control groups, with both groups having a relatively similar community structure. However, compared to the control group, the SMA group showed an increased relative abundance of the genera Ruminiclostridium, Gordonibacter, Enorma, Lawsonella, Frisingicoccus, and Anaerofilum and a decreased abundance of the genera Catabacter, Howardella, Marine_Methylotrophic_Group_3, and Lachnospiraceae_AC2044_group. The concurrent metabolomic analysis showed that the SMA group had 56 different kinds of lipid metabolite levels than did the control group. Additionally, the Spearman correlation suggested a correlation between the altered differential lipid metabolites and the above-mentioned altered microbiota. CONCLUSIONS: The gut microbiome and lipid metabolites differed between the patients with SMA and the control subjects. The altered microbiota may be related with the lipid metabolic disorders in SMA. However, further study is necessary to clarify the mechanism of lipid metabolic disorders and develop management strategies to improve the related complications in SMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00477-6. |
format | Online Article Text |
id | pubmed-10134726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-101347262023-04-28 The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy Feng, Yijie Cui, Yiqin Jin, Jianing Huang, Siyi Wei, Jia Yao, Mei Zhou, Dongming Mao, Shanshan Neurol Ther Original Research INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore the alterations in the gut microbiota in SMA and the potential relationship between altered microbiota and lipid metabolic disorders. METHODS: Fifteen patients with SMA and 17 gender- and age-matched healthy controls were enrolled in the study. Feces and fasting plasma samples were collected. 16S ribosomal RNA sequencing and nontargeted metabolomics analysis were performed to explore the correlation between microbiota and differential lipid metabolites. RESULTS: No significant difference was found in microbial diversity (α- and β-diversity) between the SMA and control groups, with both groups having a relatively similar community structure. However, compared to the control group, the SMA group showed an increased relative abundance of the genera Ruminiclostridium, Gordonibacter, Enorma, Lawsonella, Frisingicoccus, and Anaerofilum and a decreased abundance of the genera Catabacter, Howardella, Marine_Methylotrophic_Group_3, and Lachnospiraceae_AC2044_group. The concurrent metabolomic analysis showed that the SMA group had 56 different kinds of lipid metabolite levels than did the control group. Additionally, the Spearman correlation suggested a correlation between the altered differential lipid metabolites and the above-mentioned altered microbiota. CONCLUSIONS: The gut microbiome and lipid metabolites differed between the patients with SMA and the control subjects. The altered microbiota may be related with the lipid metabolic disorders in SMA. However, further study is necessary to clarify the mechanism of lipid metabolic disorders and develop management strategies to improve the related complications in SMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00477-6. Springer Healthcare 2023-04-27 /pmc/articles/PMC10134726/ /pubmed/37103747 http://dx.doi.org/10.1007/s40120-023-00477-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Feng, Yijie Cui, Yiqin Jin, Jianing Huang, Siyi Wei, Jia Yao, Mei Zhou, Dongming Mao, Shanshan The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title | The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title_full | The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title_fullStr | The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title_full_unstemmed | The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title_short | The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy |
title_sort | alterations of gut microbiome and lipid metabolism in patients with spinal muscular atrophy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134726/ https://www.ncbi.nlm.nih.gov/pubmed/37103747 http://dx.doi.org/10.1007/s40120-023-00477-6 |
work_keys_str_mv | AT fengyijie thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT cuiyiqin thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT jinjianing thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT huangsiyi thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT weijia thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT yaomei thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT zhoudongming thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT maoshanshan thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT fengyijie alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT cuiyiqin alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT jinjianing alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT huangsiyi alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT weijia alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT yaomei alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT zhoudongming alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy AT maoshanshan alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy |